Quantitative RT-PCR analysis of PSA and prostate-specific membrane antigen mRNA to detect circulating tumor cells improves recurrence-free survival nomogram prediction after radical prostatectomy

Prostate

Volumn 72, Issue 12, 2012, Pages 1382-1388

  Yates, David R ^a   Rouprêt, Morgan ^a,b,c   Drouin, Sarah J ^a,b   Comperat, Eva ^a   Ricci, Sylvie ^b   Lacave, Roger ^b   Sèbe, Philippe ^b   Cancel Tassin, Geraldine ^b,c   Bitker, Marc Olivier ^a   Cussenot, Olivier ^b,c  

^a PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^b HÔPITAL TENON   (France)

^c SORBONNE UNIVERSITÉ   (France)

Author keywords

circulating tumor cells; nomograms; prostate cancer; quantitative RT PCR

Indexed keywords

MESSENGER RNA; PROSTATE SPECIFIC ANTIGEN; PROSTATE SPECIFIC MEMBRANE ANTIGEN;

ADULT; AGED; ARTICLE; CANCER RECURRENCE; HUMAN; MAJOR CLINICAL STUDY; MALE; NOMOGRAM; PREDICTION; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATECTOMY; QUANTITATIVE ANALYSIS; RECURRENCE FREE SURVIVAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION;

AGED; ANTIGENS, SURFACE; DISEASE-FREE SURVIVAL; FOLLOW-UP STUDIES; GLUTAMATE CARBOXYPEPTIDASE II; HUMANS; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; NEOPLASTIC CELLS, CIRCULATING; NOMOGRAMS; PREDICTIVE VALUE OF TESTS; PROSTATE-SPECIFIC ANTIGEN; PROSTATECTOMY; PROSTATIC NEOPLASMS; REAL-TIME POLYMERASE CHAIN REACTION; RECURRENCE; RNA, MESSENGER; TUMOR MARKERS, BIOLOGICAL;

EID: 84864289265     PISSN: 02704137     EISSN: 10970045     Source Type: Journal    
DOI: 10.1002/pros.22488     Document Type: Article

References (44)

1. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D,. Global cancer statistics. CA Cancer J Clin 2011; 61 (2): 69-90.
2. Galper SL, Chen MH, Catalona WJ, Roehl KA, Richie JP, D'Amico AV,. Evidence to support a continued stage migration and decrease in prostate cancer specific mortality. J Urol 2006; 175 (3 Pt 1): 907-912. (Pubitemid 43200015)
3. Heidenreich A, Bellmunt J, Bolla M, Joniau S, Mason M, Matveev V, Mottet N, Schmid HP, van der Kwast T, Wiegel T, Zattoni F,. EAU guidelines on prostate cancer. Part 1: Screening, diagnosis, and treatment of clinically localised disease. Eur Urol 2011; 59 (1): 61-71.
4. Han M, Partin AW, Zahurak M, Piantadosa S, Epstein JI, Walsh PC,. Biochemical (Prostate Specific Antigen) recurrence probability following radical prostatectomy for clinically localised prostate cancer. J Urol 2003; 169 (2): 517-523. (Pubitemid 36132976)
5. Kattan MW, Eastham JA, Stapleton AM, Wheeler TM, Scardino PT,. A preoperative nomogram for disease recurrence following radical prostatectomy for prostate cancer. J Natl Cancer Inst 1998; 90 (10): 766-771. (Pubitemid 28259189)
6. Kattan MW, Wheeler TM, Scardino PT,. Postoperative nomogram for disease recurrence after radical prostatectomy for prostate cancer. J Clin Oncol 1999; 17 (5): 1499-1507. (Pubitemid 29220858)
7. Epstein JI,. An update of the Gleason scoring system. J Urol 2010; 183 (2): 433-440.
8. Fine SW, Epstein JI,. A contemporary study correlating prostate needle biopsy and radical prostatectomy Gleason score. J Urol 2008; 179 (4): 1335-1339 discussion 38-39.
9. Hernandez J, Canby-Hagino E, Thompson IM,. Biomarkers for the detection and prognosis of prostate cancer. Curr Urol Rep 2005; 6 (3): 171-176.
10. Fiorentino M, Capizzi E, Loda M,. Blood and tissue biomarkers in prostate cancer: State of the art. Urol Clin North Am 2010; 37 (1): 131-141.
11. Kawasaki ES, Clark SS, Coyne MY, Smith SD, Champlin R, Witte ON, McCormick FP,. Diagnosis of chronic myeloid and acute lymphocytic leukemias by detection of leukemia-specific mRNA sequences amplified in vitro. Proc Natl Acad Sci USA 1988; 85 (15): 5698-5702.
12. Moreno JG, Croce CM, Fischer R, Monne M, Vihko P, Mulholland SG, Gomella LG,. Detection of hematogenous micrometastasis in patients with prostate cancer. Cancer Res 1992; 52 (21): 6110-6112.
13. Katz AE, Olsson CA, Raffo AJ, Cama C, Perlman H, Seaman E, O'Toole KM, McMahon D, Benson MC, Buttyan R,. Molecular staging of prostate cancer with the use of an enhanced reverse transcriptase-PCR assay. Urology 1994; 43 (6): 765-775. (Pubitemid 24174463)
14. Tombal B, Van Cangh PJ, Loric S, Gala JL,. Prognostic value of circulating prostate cells in patients with a rising PSA after radical prostatectomy. Prostate 2003; 56 (3): 163-170. (Pubitemid 36918166)
15. Olsson CA, de Vries GM, Raffo AJ, Benson MC, O'Toole K, Cao Y, Buttyan RE, Katz AE,. Preoperative reverse transcriptase polymerase chain reaction for prostate specific antigen predicts treatment failure following radical prostatectomy. J Urol 1996; 155 (5): 1557-1562. (Pubitemid 26126948)
16. Grasso YZ, Gupta MK, Levin HS, Zippe CD, Klein EA,. Combined nested RT-PCR assay for prostate-specific antigen and prostate-specific membrane antigen in prostate cancer patients: Correlation with pathological stage. Cancer Res 1998; 58 (7): 1456-1459. (Pubitemid 28193608)
17. Kollermann J, Weikert S, Schostak M, Kempkensteffen C, Kleinschmidt K, Rau T, Pantel K,. Prognostic significance of disseminated tumor cells in the bone marrow of prostate cancer patients treated with neoadjuvant hormone treatment. J Clin Oncol 2008; 26 (30): 4928-4933.
18. de Bono JS, Scher HI, Montgomery RB, Parker C, Miller MC, Tissing H, Doyle GV, Terstappen LW, Pienta KJ, Raghavan D,. Circulating tumor cells predict survival benefit from treatment in metastatic castration-resistant prostate cancer. Clin Cancer Res 2008; 14 (19): 6302-6309.
19. Danila DC, Heller G, Gignac GA, Gonzalez-Espinoza R, Anand A, Tanaka E, Lilja H, Schwartz L, Larson S, Fleisher M, Scher HI,. Circulating tumor cell number and prognosis in progressive castration-resistant prostate cancer. Clin Cancer Res 2007; 13 (23): 7053-7058. (Pubitemid 350276887)
20. Okegawa T, Nutahara K, Higashihara E,. Immunomagnetic quantification of circulating tumor cells as a prognostic factor of androgen deprivation responsiveness in patients with hormone naive metastatic prostate cancer. J Urol 2008; 180 (4): 1342-1347.
21. Kurek R, Nunez G, Tselis N, Konrad L, Martin T, Roeddiger S, Aumuller G, Zamboglou N, Lin DW, Tunn UW, Renneberg H,. Prognostic value of combined "triple"-reverse transcription-PCR analysis for prostate-specific antigen, human kallikrein 2, and prostate-specific membrane antigen mRNA in peripheral blood and lymph nodes of prostate cancer patients. Clin Cancer Res 2004; 10 (17): 5808-5814. (Pubitemid 39180959)
22. Reid AH, Attard G, Danila DC, Oommen NB, Olmos D, Fong PC, Molife LR, Hunt J, Messiou C, Parker C, Dearnaley D, Swennenhuis JF, Terstappen LW, Lee G, Kheoh T, Molina A, Ryan CJ, Small E, Scher HI, de Bono JS,. Significant and sustained antitumor activity in post-docetaxel, castration-resistant prostate cancer with the CYP17 inhibitor abiraterone acetate. J Clin Oncol 2010; 28 (9): 1489-1495.
23. Danila DC, Fleisher M, Scher HI,. Circulating tumor cells as biomarkers in prostate cancer. Clin Cancer Res 2011; 17 (12): 3903-3912.
24. Kruck S, Gakis G, Stenzl A,. Circulating and disseminated tumor cells in the management of advanced prostate cancer. Adv Urol 2012; 2012: 135281.
25. Sehdev AE, Pan CC, Epstein JI,. Comparative analysis of sampling methods for grossing radical prostatectomy specimens performed for nonpalpable (stage T1c) prostatic adenocarcinoma. Hum Pathol 2001; 32 (5): 494-499. (Pubitemid 32506519)
26. Fromont G, Chene L, Vidaud M, Vallancien G, Mangin P, Fournier G, Validire P, Latil A, Cussenot O,. Differential expression of 37 selected genes in hormone-refractory prostate cancer using quantitative taqman real-time RT-PCR. Int J Cancer 2005; 114 (2): 174-181. (Pubitemid 40194283)
27. Zhang L, Wang CY, Yang R, Shi J, Fu R, Chen L, Klocker H, Zhang J,. Real-time quantitative RT-PCR assay of prostate-specific antigen and prostate-specific membrane antigen in peripheral blood for detection of prostate cancer micrometastasis. Urol Oncol 2008; 26 (6): 634-640.
28. Llanes L, Ferruelo A, Lujan M, Pascual C, Garcia-Mediero JM, Berenguer A,. Quantitative real-time reverse transcription: Polymerase chain reaction of prostate-specific antigen (PSA) for detection of circulating prostatic cells in patients with clinically localized prostate cancer. Prostate Cancer Prostatic Dis 2005; 8 (3): 248-252. (Pubitemid 43118062)
29. Capitanio U, Jeldres C, Shariat SF, Karakiewicz P,. Clinicians are most familiar with nomograms and rate their clinical usefulness highest, look-up tables are second best. Eur Urol 2008; 54 (4): 958-959.
30. Ross PL, Gerigk C, Gonen M, Yossepowitch O, Cagiannos I, Sogani PC, Scardino PT, Kattan MW,. Comparisons of nomograms and urologists' predictions in prostate cancer. Semin Urol Oncol 2002; 20 (2): 82-88. (Pubitemid 34522545)
31. Karakiewicz PI, Briganti A, Chun FK, Trinh QD, Perrotte P, Ficarra V, Cindolo L, De la Taille A, Tostain J, Mulders PF, Salomon L, Zigeuner R, Prayer-Galetti T, Chautard D, Valeri A, Lechevallier E, Descotes JL, Lang H, Mejean A, Patard JJ,. Multi-institutional validation of a new renal cancer-specific survival nomogram. J Clin Oncol 2007; 25 (11): 1316-1322. (Pubitemid 46706877)
32. Shariat SF, Karakiewicz PI, Palapattu GS, Amiel GE, Lotan Y, Rogers CG, Vazina A, Bastian PJ, Gupta A, Sagalowsky AI, Schoenberg M, Lerner SP,. Nomograms provide improved accuracy for predicting survival after radical cystectomy. Clin Cancer Res 2006; 12 (22): 6663-6676. (Pubitemid 44876834)
33. Zini L, Cloutier V, Isbarn H, Perrotte P, Capitanio U, Jeldres C, Shariat SF, Saad F, Arjane P, Duclos A, Lattouf JB, Montorsi F, Karakiewicz PI,. A simple and accurate model for prediction of cancer-specific mortality in patients treated with surgery for primary penile squamous cell carcinoma. Clin Cancer Res 2009; 15 (3): 1013-1018.
34. Graefen M, Karakiewicz PI, Cagiannos I, Klein E, Kupelian PA, Quinn DI, Henshall SM, Grygiel JJ, Sutherland RL, Stricker PD, de Kernion J, Cangiano T, Schroder FH, Wildhagen MF, Scardino PT, Kattan MW,. Validation study of the accuracy of a postoperative nomogram for recurrence after radical prostatectomy for localized prostate cancer. J Clin Oncol 2002; 20 (4): 951-956. (Pubitemid 34141837)
35. Stephenson AJ, Scardino PT, Eastham JA, Bianco FJ Jr, Dotan ZA, DiBlasio CJ, Reuther A, Klein EA, Kattan MW,. Postoperative nomogram predicting the 10-year probability of prostate cancer recurrence after radical prostatectomy. J Clin Oncol 2005; 23 (28): 7005-7012.
36. D'Amico AV, Chen MH, Roehl KA, Catalona WJ,. Identifying patients at risk for significant versus clinically insignificant postoperative prostate-specific antigen failure. J Clin Oncol 2005; 23 (22): 4975-4979. (Pubitemid 46224003)
37. Swanson GP, Yu C, Kattan MW, Hermans MR,. Validation of postoperative nomograms in prostate cancer patients with long-term follow-up. Urology 78 (1): 105-109.
38. Collette L,. Prostate-specific antigen (PSA) as a surrogate end point for survival in prostate cancer clinical trials. Eur Urol 2008; 53 (1): 6-9. (Pubitemid 350166730)
39. Favaretto RL, Shariat SF, Savage C, Godoy G, Chade DC, Kaag M, Bochner BH, Coleman J, Dalbagni G,. Combining imaging and ureteroscopy variables in a preoperative multivariable model for prediction of muscle-invasive and non-organ confined disease in patients with upper tract urothelial carcinoma. BJU Int 2012; 109 (1): 77-82.
40. Shariat SF, Walz J, Roehrborn CG, Zlotta AR, Perrotte P, Suardi N, Saad F, Karakiewicz PI,. External validation of a biomarker-based preoperative nomogram predicts biochemical recurrence after radical prostatectomy. J Clin Oncol 2008; 26 (9): 1526-1531.
41. Sardana G, Dowell B, Diamandis EP,. Emerging biomarkers for the diagnosis and prognosis of prostate cancer. Clin Chem 2008; 54 (12): 1951-1960. (Pubitemid 352774027)
42. Thiounn N, Saporta F, Flam TA, Pages F, Zerbib M, Vieillefond A, Martin E, Debre B, Chevillard S,. Positive prostate-specific antigen circulating cells detected by reverse transcriptase-polymerase chain reaction does not imply the presence of prostatic micrometastases. Urology 1997; 50 (2): 245-250. (Pubitemid 27339941)
43. Kalfazade N, Kuskucu AM, Karadag S, Sahin S, Aras B, Midilli K, Yilmaz G, Tasci AI,. Quantification of PSA mRNA levels in peripheral blood of patients with localized prostate adenocarcinoma before, during, and after radical prostatectomy by quantitative real-time PCR (qRT-PCR). Int Urol Nephrol 2009; 41 (2): 273-279.
44. Okegawa T, Nutahara K, Higashihara E,. Prognostic significance of circulating tumor cells in patients with hormone refractory prostate cancer. J Urol 2009; 181 (3): 1091-1097.